Evotec SE ADR (EVO)vsZoetis Inc (ZTS)
EVO
Evotec SE ADR
$2.85
-5.72%
HEALTHCARE · Cap: $975.56M
ZTS
Zoetis Inc
$72.47
-0.10%
HEALTHCARE · Cap: $32.77B
Smart Verdict
WallStSmart Research — data-driven comparison
Zoetis Inc generates 1179% more annual revenue ($9.53B vs $745.04M). ZTS leads profitability with a 28.0% profit margin vs -26.0%. EVO appears more attractively valued with a PEG of 1.42. ZTS earns a higher WallStSmart Score of 66/100 (B-).
EVO
Hold35
out of 100
Grade: F
ZTS
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for EVO.
Margin of Safety
+11.5%
Fair Value
$145.45
Current Price
$72.47
$72.98 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Every $100 of equity generates 82 in profit
Strong operational efficiency at 36.6%
Safe zone — low bankruptcy risk
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -28.0% — below average capital efficiency
Revenue declined 21.7%
Expensive relative to growth rate
Trading at 9.2x book value
2.9% revenue growth
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : EVO
The strongest argument for EVO centers on Price/Book. PEG of 1.42 suggests the stock is reasonably priced for its growth.
Bull Case : ZTS
The strongest argument for ZTS centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 28.0% and operating margin at 36.6%.
Bear Case : EVO
The primary concerns for EVO are EPS Growth, Market Cap, Return on Equity.
Bear Case : ZTS
The primary concerns for ZTS are PEG Ratio, Price/Book, Revenue Growth. Debt-to-equity of 2.86 is elevated, increasing financial risk.
Key Dynamics to Monitor
EVO profiles as a turnaround stock while ZTS is a value play — different risk/reward profiles.
EVO carries more volatility with a beta of 1.30 — expect wider price swings.
ZTS is growing revenue faster at 2.9% — sustainability is the question.
ZTS generates stronger free cash flow (291M), providing more financial flexibility.
Bottom Line
ZTS scores higher overall (66/100 vs 35/100), backed by strong 28.0% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Evotec SE ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Evotec SE is a prominent global biotechnology company headquartered in Hamburg, Germany, specializing in delivering comprehensive drug discovery and development solutions to the pharmaceutical and biotech industries. The firm is distinguished by its collaborative strategy, forming partnerships with leading pharmaceutical entities and prestigious academic institutions to accelerate the progress of a diverse range of therapeutic programs, including small molecules, biologics, and cell therapies. With a strong and growing pipeline, Evotec is strategically positioned to leverage new opportunities within the biopharmaceutical sector, reaffirming its essential contribution to healthcare innovation and improved patient outcomes.
Zoetis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?